Unilever stock price rises in London despite Trump tariff jitters — what to watch before earnings
19 January 2026
1 min read

Unilever stock price rises in London despite Trump tariff jitters — what to watch before earnings

London, Jan 19, 2026, 08:47 GMT — Regular session

  • Unilever shares climbed roughly 0.7% in early London trading, defying the wider European selloff
  • Markets jolted as U.S. President Donald Trump threatened to impose new tariffs linked to Greenland
  • Investors are eyeing Unilever’s Feb. 12 earnings for clues on its growth and margin outlook

Unilever (ULVR.L) shares climbed roughly 0.7% to 4,793 pence in early London trade Monday, showing resilience amid risk-off headlines sweeping Europe. The stock has slipped about 1.4% year to date. 1

The pan-European STOXX 600 slid 1.3%, while London’s FTSE 100 dipped 0.4% following U.S. President Donald Trump’s threat to impose more tariffs if the U.S. isn’t allowed to buy Greenland. Trump announced a 10% tariff starting Feb. 1 on goods from several European countries, set to jump to 25% on June 1 if no agreement is reached. U.S. markets were closed Monday for Martin Luther King Jr. Day. ING economists noted, “The rationale for higher tariffs is now even more political and less economic.” 2

Timing is crucial for Unilever investors. Consumer staples—firms selling everyday essentials—often attract buyers during bouts of market jitters. Yet, that same churn can rattle currency markets and shake up pricing expectations for global companies.

Unilever is a global consumer goods company with a diverse portfolio covering personal care, home care, and foods. Its personal care lineup includes brands like Dove and TRESemme, while in home care, it owns names such as Cif and Domestos. 3

Unilever’s next major event is the release of its full-year results. The company plans to report fourth-quarter and full-year 2025 figures on Feb. 12. CEO Fernando Fernandez is also scheduled to present at the Consumer Analyst Group of New York (CAGNY) conference on Feb. 17. 4

Before releasing its results, Unilever directed investors to a “pre-close aide-mémoire”—a summary of already disclosed or public information—and stressed it offers no new trading update or guidance. The company is gathering analyst consensus to share at a later date. 5

Traders are watching closely for signs of how much of last year’s price gains have endured, if volumes are picking up, and what Unilever reveals about input costs and promotions in its main markets.

There’s a risk angle here, too. Safe-haven flows surged after the tariff threat, with analysts cautioning that uncertainty may linger even if the details shift. Vishnu Varathan, head of macro research at Mizuho, said it “throws the so-called agreements out of the window.” Charu Chanana, chief investment strategist at Saxo, warned that “uncertainty can make companies delay capex and supply-chain decisions” — capex being capital spending. 6

Unilever is navigating a significant shakeup. After spinning off its Magnum ice cream unit in December, the company completed an 8-for-9 share consolidation, Reuters reported. 7

The calendar lays it out plainly, though the tape less so: all eyes on Trump’s Feb. 1 tariff deadline for signs of follow-through. Then comes Unilever’s Feb. 12 earnings report, offering a fresh snapshot of sales growth and margins.

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Diageo share price slips after $22bn spirits glut report — here’s what traders watch next
Previous Story

Diageo share price slips after $22bn spirits glut report — here’s what traders watch next

BAE Systems share price rises after buyback update as defence stocks hold up
Next Story

BAE Systems share price rises after buyback update as defence stocks hold up

Go toTop